Global Anticoagulants Market: Size, Trends & Forecasts (2019-2023 Edition)
SCOPE OF THE REPORT
The report entitled “Global Anticoagulants Market (2019-2023 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by segment, and by products.
The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.
A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.
Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2019-2023, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.
Company Coverage
Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.
The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2019-2023, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.
The report entitled “Global Anticoagulants Market (2019-2023 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by segment, and by products.
The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.
A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.
Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2019-2023, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.
Company Coverage
- Bayer
- BMS/Pfizer
- Boehringher Ingelheim
- Daiichi Sankyo
- The US
Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.
The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2019-2023, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
2.1.2 Novel Oral Anticoagulants
3. GLOBAL MARKET ANALYSIS
3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market by Countries (The US and Rest of the World)
3.1.3 Global Anticoagulants Market Share by Segment
3.1.4 Global Anticoagulants Market Share by Products
4. GLOBAL ANTICOAGULANTS PRODUCT ANALYSIS
4.1 Oral Anticoagulants Product Analysis
4.1.1 Global Oral Anticoagulants Market by Value
4.1.2 Global Xarelto Market by Value
4.1.3 Global Xarelto Market Value by Region (North America and Rest of the World)
4.1.4 Global Eliquis Market by Value
4.1.5 Global Pradaxa Market by Value
4.1.6 Global Savaysa Market by Value
4.2 Injectable Anticoagulants Product Analysis
4.2.1 Global Lovenox Market by Value
4.2.2 Global Arixtra Market by Value
5. REGION/COUNTRY ANALYSIS
5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Anticoagulants Market by Products
5.1.3 The US Xarelto Market by Value
5.1.4 The US Eliquis Market by Value
5.1.5 The US Pradaxa Market by Value
5.1.6 The US Savaysa Market by Value
6. COMPETITIVE LANDSCAPE
6.1 Global Anticoagulants Market Players by Product Comparison
7. COMPANY PROFILES
7.1 Bayer Group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 BMS/Pfizer
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Boehringher Ingelheim
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Daiichi Sankyo
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
2.1.2 Novel Oral Anticoagulants
3. GLOBAL MARKET ANALYSIS
3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market by Countries (The US and Rest of the World)
3.1.3 Global Anticoagulants Market Share by Segment
3.1.4 Global Anticoagulants Market Share by Products
4. GLOBAL ANTICOAGULANTS PRODUCT ANALYSIS
4.1 Oral Anticoagulants Product Analysis
4.1.1 Global Oral Anticoagulants Market by Value
4.1.2 Global Xarelto Market by Value
4.1.3 Global Xarelto Market Value by Region (North America and Rest of the World)
4.1.4 Global Eliquis Market by Value
4.1.5 Global Pradaxa Market by Value
4.1.6 Global Savaysa Market by Value
4.2 Injectable Anticoagulants Product Analysis
4.2.1 Global Lovenox Market by Value
4.2.2 Global Arixtra Market by Value
5. REGION/COUNTRY ANALYSIS
5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Anticoagulants Market by Products
5.1.3 The US Xarelto Market by Value
5.1.4 The US Eliquis Market by Value
5.1.5 The US Pradaxa Market by Value
5.1.6 The US Savaysa Market by Value
6. COMPETITIVE LANDSCAPE
6.1 Global Anticoagulants Market Players by Product Comparison
7. COMPANY PROFILES
7.1 Bayer Group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 BMS/Pfizer
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Boehringher Ingelheim
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Daiichi Sankyo
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Anticoagulants
Figure 2: Global Anticoagulants Market by Value; 2014-2018 (US$ Billion)
Figure 3: Global Anticoagulants Market by Value; 2019-2023 (US$ Billion)
Figure 4: Global Anticoagulants Market by Countries; 2018 (Percentage, %)
Figure 5: Global Anticoagulants Market Share by Segment; 2018 (Percentage, %)
Figure 6: Global Anticoagulants Market Share by Products; 2018(Percentage, %)
Figure 7: Global Oral Anticoagulants Market by Value; 2016-2018 (US$ Billion)
Figure 8: Global Xarelto Market by Value; 2016-2018 (US$ Billion)
Figure 9: Global Xarelto Market by Value; 2019-2023 (US$ Billion)
Figure 10: Global Xarelto Market Value by Region; 2018 (Percentage, %)
Figure 11: Global Eliquis Market by Value; 2015-2018 (US$ Billion)
Figure 12: Global Eliquis Market by Value; 2019-2023 (US$ Billion)
Figure 13: Global Pradaxa Market by Value; 2016-2018 (US$ Billion)
Figure 14: Global Savaysa Market by Value; 2016-2018 (US$ Million)
Figure 15: Global Savaysa Market by Value; 2019-2023 (US$ Million)
Figure 16: Global Lovenox Market by Value; 2013-2018 (US$ Billion)
Figure 17: Global Arixtra Market by Value; 2015-2017 (US$ Million)
Figure 18: The US Anticoagulants Market by Value; 2016-2018 (US$ Billion)
Figure 19: The US Anticoagulants Market by Value; 2019-2023 (US$ Billion)
Figure 20: The US Anticoagulants Market by Products; 2018 (Percentage, %)
Figure 21: The US Xarelto Market by Value; 2016-2018 (US$ Billion)
Figure 22: The US Xarelto Market by Value; 2019-2023 (US$ Billion)
Figure 23: The US Eliquis Market by Value; 2016-2018 (US$ Billion)
Figure 24: The US Eliquis Market by Value; 2019-2023 (US$ Billion)
Figure 25: The US Pradaxa Market by Value; 2016-2018 (US$ Million)
Figure 26: The US Pradaxa Market by Value; 2019-2023 (US$ Million)
Figure 27: The US Savaysa Market by Value; 2016-2018 (US$ Million)
Figure 28: The US Savaysa Market by Value; 2019-2023 (US$ Million)
Figure 29: Bayer Group Net Sales; 2014-2018 (US$ Billion)
Figure 30: Bayer Group Net Sales by Segment; 2018 (Percentage, %)
Figure 31: Bayer Group Net Sales by Geography; 2018 (Percentage, %)
Figure 32: BMS-Pfizer Alliance Revenue; 2014-2018 (US$ Billion)
Figure 33: BMS Revenue by Geography; 2018 (Percentage, %)
Figure 34: BMS Revenue by Product; 2018 (Percentage, %)
Figure 35: Boehringer Ingelheim Sales; 2014-2018 (US$ Billion)
Figure 36: Boehringer Ingelheim Sales by Segments; 2018
Figure 37: Boehringer Ingelheim Sales by Geography; 2018
Figure 38: Daiichi Sankyo Co., Ltd. Revenue; 2014-2018 (US$ Billion)
Figure 39: Daiichi Sankyo Co., Ltd. Revenue by Products; 2018 (Percentage, %)
Figure 40: Daiichi Sankyo Co., Ltd. Revenue by Region; 2018 (Percentage, %)
Table 1: Unfractionated Heparin vs Low Molecular Weight Heparin
Table 2: List of Intravenous/Subcutaneous Anticoagulants
Table 3: List of Oral Anticoagulants (NOCAs)
Table 4: Global Anticoagulants Market Players by Product Comparison
Table 5: Bayer Group Product and Activities of Pharmaceutical Segment
Table 6: Xarelto Research and Development Project (Phase III)
Figure 1: Types of Anticoagulants
Figure 2: Global Anticoagulants Market by Value; 2014-2018 (US$ Billion)
Figure 3: Global Anticoagulants Market by Value; 2019-2023 (US$ Billion)
Figure 4: Global Anticoagulants Market by Countries; 2018 (Percentage, %)
Figure 5: Global Anticoagulants Market Share by Segment; 2018 (Percentage, %)
Figure 6: Global Anticoagulants Market Share by Products; 2018(Percentage, %)
Figure 7: Global Oral Anticoagulants Market by Value; 2016-2018 (US$ Billion)
Figure 8: Global Xarelto Market by Value; 2016-2018 (US$ Billion)
Figure 9: Global Xarelto Market by Value; 2019-2023 (US$ Billion)
Figure 10: Global Xarelto Market Value by Region; 2018 (Percentage, %)
Figure 11: Global Eliquis Market by Value; 2015-2018 (US$ Billion)
Figure 12: Global Eliquis Market by Value; 2019-2023 (US$ Billion)
Figure 13: Global Pradaxa Market by Value; 2016-2018 (US$ Billion)
Figure 14: Global Savaysa Market by Value; 2016-2018 (US$ Million)
Figure 15: Global Savaysa Market by Value; 2019-2023 (US$ Million)
Figure 16: Global Lovenox Market by Value; 2013-2018 (US$ Billion)
Figure 17: Global Arixtra Market by Value; 2015-2017 (US$ Million)
Figure 18: The US Anticoagulants Market by Value; 2016-2018 (US$ Billion)
Figure 19: The US Anticoagulants Market by Value; 2019-2023 (US$ Billion)
Figure 20: The US Anticoagulants Market by Products; 2018 (Percentage, %)
Figure 21: The US Xarelto Market by Value; 2016-2018 (US$ Billion)
Figure 22: The US Xarelto Market by Value; 2019-2023 (US$ Billion)
Figure 23: The US Eliquis Market by Value; 2016-2018 (US$ Billion)
Figure 24: The US Eliquis Market by Value; 2019-2023 (US$ Billion)
Figure 25: The US Pradaxa Market by Value; 2016-2018 (US$ Million)
Figure 26: The US Pradaxa Market by Value; 2019-2023 (US$ Million)
Figure 27: The US Savaysa Market by Value; 2016-2018 (US$ Million)
Figure 28: The US Savaysa Market by Value; 2019-2023 (US$ Million)
Figure 29: Bayer Group Net Sales; 2014-2018 (US$ Billion)
Figure 30: Bayer Group Net Sales by Segment; 2018 (Percentage, %)
Figure 31: Bayer Group Net Sales by Geography; 2018 (Percentage, %)
Figure 32: BMS-Pfizer Alliance Revenue; 2014-2018 (US$ Billion)
Figure 33: BMS Revenue by Geography; 2018 (Percentage, %)
Figure 34: BMS Revenue by Product; 2018 (Percentage, %)
Figure 35: Boehringer Ingelheim Sales; 2014-2018 (US$ Billion)
Figure 36: Boehringer Ingelheim Sales by Segments; 2018
Figure 37: Boehringer Ingelheim Sales by Geography; 2018
Figure 38: Daiichi Sankyo Co., Ltd. Revenue; 2014-2018 (US$ Billion)
Figure 39: Daiichi Sankyo Co., Ltd. Revenue by Products; 2018 (Percentage, %)
Figure 40: Daiichi Sankyo Co., Ltd. Revenue by Region; 2018 (Percentage, %)
Table 1: Unfractionated Heparin vs Low Molecular Weight Heparin
Table 2: List of Intravenous/Subcutaneous Anticoagulants
Table 3: List of Oral Anticoagulants (NOCAs)
Table 4: Global Anticoagulants Market Players by Product Comparison
Table 5: Bayer Group Product and Activities of Pharmaceutical Segment
Table 6: Xarelto Research and Development Project (Phase III)
